Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia

Schizophrenia Research

Volumn 77, Issue 2-3, 2005, Pages 119-128

  Gharabawi, Georges M ^a,c   Bossie, Cynthia A ^a   Lasser, Robert A ^a   Turkoz, Ibrahim ^a   Rodriguez, Stephen ^a   Chouinard, Guy ^b  

^a Medical Affairs Division   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c NONE   (United States)

Author keywords

Abnormal Involuntary Movement Scale (AIMS); Extrapyramidal Symptom Rating Scale (ESRS); Movement disorder; Schizophrenia; Tardive dyskinesia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INTERMETHOD COMPARISON; INVOLUNTARY MOVEMENT; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

ADOLESCENT; ADULT; AGED; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 23444456327     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.03.008     Document Type: Article

References (21)

1. C.M. Beasley, M.A. Dellva, R.N. Tamura, H. Morgenstern, W.M. Glazer, K. Ferguson, and G.D. Tollefson Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol Br. J. Psychiatry 174 1999 23 30
2. G. Chouinard New nomenclature for drug-induced movement disorders including tardive dyskinesia J. Clin. Psychiatry 65 Suppl. 9 2004 9 15
3. G. Chouinard, L. Annable, A. Ross-Chouinard, and J.N. Nestoros Factors related to tardive dyskinesia Am. J. Psychiatry 136 1979 79 82
4. G. Chouinard, A. Ross-Chouinard, L. Annable, and B. Jones Extrapyramidal Symptom Rating Scale Can. J. Neurol. Sci. 7 1980 234
5. G. Chouinard, L. Annable, A. Ross-Chouinard, and P. Mercier A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases J. Clin. Psychopharmacol. 8 1988 21S 26S
6. G. Chouinard, R. Lasser, C. Bossie, Y. Zhu, and G. Gharabawi Does a long-acting atypical antipsychotic offer a low risk of tardive dyskinesia in patients with schizophrenia? Biol. Psychiatry 53 2003 81S 82S
7. C.U. Correll, S. Leucht, and J.M. Kane Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies Am. J. Psychiatry 161 2004 414 425
8. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revised (DSM-IV-TR), 2000. American Psychiatric Association, Washington, DC, pp. 803-805.
9. W.M. Glazer Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality J. Clin. Psychiatry 61 2000 16 21
10. W.A. Guy Abnormal Involuntary Movement Scale (AIMS) ECDEU Assessment Manual for Psychopharmacology 1976 U.S. Department of Health Education and Welfare Washington, DC 534 537
11. D.V. Jeste, and M.P. Caligiuri Tardive dyskinesia Schizophr. Bull. 19 1993 303 315
12. D.V. Jeste, W.M. Glazer, H. Morgenstern, J.A. Pultz, and P.P. Yeung Rarity of tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly Poster Presented at the 38th Annual Meeting of the American College of Neuropsychopharmacology Acapulco, Mexico, December 12-16 1999
13. D.V. Jeste, J.P. Lacro, A. Bailey, E. Rockwell, M.J. Harris, and M.P. Caligiuri Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients J. Am. Geriatr. Soc. 47 1999 716 719
14. D.V. Jeste, E. Rockwell, M.J. Harris, J.B. Lohr, and J. Lacro Conventional vs. newer antipsychotics in elderly patients Am. J. Geriatr. Psychiatry 7 1999 70 76
15. D.V. Jeste, A. Okamoto, J. Napolitano, J.M. Kane, and R.A. Martinez Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone Am. J. Psychiatry 157 2000 1150 1155
16. J.M. Kane Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence J. Clin. Psychiatry 65 Suppl. 9 2004 16 20
17. A.J. Loonen, C.H. Doorschot, D.A. van Hemert, M.C. Oostelbos, and A.E. Sijben The schedule for the Aassessment of Drug-induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity Int. J. Neuropsychopharmacol. 3 2000 285 296
18. H. Morgenstern, and W.M. Glazer Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study Arch. Gen. Psychiatry 50 1993 723 733
19. N.R. Schooler, and J.M. Kane Research diagnoses for tardive dyskinesia (Letter.) Arch. Gen. Psychiatry 39 1982 486 487
20. K.D. Sethi Movement disorders induced by dopamine blocking agents Semin. Neurol. 21 2001 59 68
21. G.D. Tollefson, C.M. Beasley Jr., R.N. Tamura, P.V. Tran, and J.H. Potvin Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol Am. J. Psychiatry 154 1997 1248 1254